The Efficacy of Pancreatic Duct Stenting With Rectal Indomethacin in Preventing Post-ERCP Pancreatitis
Status:
Completed
Trial end date:
2021-08-18
Target enrollment:
Participant gender:
Summary
With the development of endoscopic technology, ERCP has been widely used in the diagnosis and
treatment of pancreatobiliary diseases, and has become the first treatment for most of the
biliary and pancreatic diseases. Postoperative ERCP pancreatitis (PEP) is the most common and
serious complication after ERCP. The purpose of this study was to explore methods for
preventing postoperative pancreatitis.
1. Participants: Patients with high-risk factors associated with PEP were included in the
no-obvious patients who underwent therapeutic ERCP in our hospital from June 2018 to
December 2019.
2. Research methods: Patients were randomly divided into indometacin suppositories,
indomethacin suppositories and pancreatic stents.
3. Statistical methods: SPSS 13.0 statistical software was used. The measurement data was
expressed as x± s, and t-test or non-parametric test was used. Chi-square test was used
for count data.